Citations

Showing 10 of 108094 citations.

Surface contamination of counting tools after mock dispensing of cyclophosphamide in a simulated outpatient pharmacy
Chaffee, Bruce W., Lander, Michael J, Christen, Catherine, Redic, Kimberly

Mayo Clinic

Journal of Oncology Pharmacy Practice | March 29, 2018 | Volume: 25 | Issue: 1 | Pages: 85-93

10.1177/1078155218764587 | PMID 29592766 Get It

Purpose The primary aim was to determine if dispensing of cyclophosphamide tablets resulted in accumulated residue on pharmacy counting tools during a simulated outpatient dispensing process. Secondary objectives included determining if cyclophosphamide contamination exceeded a defined threshold level of 1 ng/cm 2 and if a larger number of prescriptions dispensed resulted in increased contamination. Methods Mock prescriptions of 40 cyclophosphamide 50 mg tablets were counted on clean trays in three scenarios using a simulated outpatient pharmacy after assaying five cleaned trays as controls. The three scenarios consisted of five simulated dispensings of one, three, or six prescriptions dispensed per scenario. Wipe samples of trays and spatulas were collected and assayed for all trays, including the five clean trays used as controls. Contamination was defined as an assayed cyclophosphamide level at or above 0.001 ng/cm 2 and levels above 1 ng/cm 2 were considered sufficient to cause risk of human uptake. Mean contamination for each scenario was calculated and compared using one-way analysis of variance. P-values of < 0.05 implied significance. Results Mean cyclophosphamide contamination on trays used to count one, three, and six cyclophosphamide prescriptions was 0.51 ± 0.10 (p=0.0003), 1.02 ± 0.10 (p < 0.0001), and 1.82 ± 0.10 ng/cm 2 (p < 0.0001), respectively. Control trays did not show detectable cyclophosphamide contamination. Increasing the number of prescriptions dispensed from 1 to 3, 1 to 6, and 3 to 6 counts increased contamination by 0.51 ± 0.15 (p = 0.0140), 1.31 + 0.15 (p < 0.0001), and 0.80 ± 0.15 ng/cm 2 (p = 0.0004), respectively. Conclusion Dispensing one or more prescriptions of 40 cyclophosphamide 50 mg tablets contaminates pharmacy counting tools, and an increased number of prescriptions dispensed correlates with increased level of contamination. Counting out three or more prescriptions leads to trays having contamination that surpasses the threshold at which worker exposure may be increased. Pharmacies should consider devoting a separate tray to cyclophosphamide tablets, as cross-contamination could occur with other drugs and the efficacy of decontamination methods is unclear. Employee exposure could be minimized with the use of personal protective equipment, environmental controls, and cleaning trays between uses. Future investigation should assess the extent of drug powder dispersion, the effects of various cleaning methods, and the potential extent of contamination with different oral cytotoxic drugs.
Constrictive Bronchiolitis in Patients With Primary Sjögren Syndrome
Wight, Elizabeth C. , Baqir, Misbah , Ryu, Jay H. , Ryu, Jay H

Mayo Clinic

JCR: Journal of Clinical Rheumatology | March 29, 2018 | Volume: 25 | Issue: 2 | Pages: 74-77

10.1097/rhu.0000000000000771 | PMID 29596206 Get It

ObjectiveConstrictive bronchiolitis (CB) is a poorly understood pulmonary manifestation of primary Sjögren syndrome (pSS). We aimed to clarify the presenting clinicoradiologic features and clinical course of pSS-associated CB through a retrospective cohort study.MethodsWe retrospectively identified 11 patients with pSS and CB (defined by mosaic pattern with air trapping on computed tomography) encountered at our institution over 9 years from 2007 to 2015. Presenting clinical features, laboratory results, radiologic findings, and clinical course were analyzed.ResultsOur patients were mostly women (91%), with a median age 53 years (range, 31–76 years) at the time of pulmonary symptom (dyspnea or cough) onset. Most (64%) were nonsmokers. Average interval between diagnosis of pSS and the onset of pulmonary symptoms was 4.4 years; in 4 patients (36%), CB was the presenting manifestation of pSS. Chest radiographs were normal (67%) or demonstrated hyperinflation (33%). Pulmonary function testing demonstrated airflow obstruction in 7 patients (63%), and 2 patients (18%) had an isolated reduction in diffusing capacity, whereas the remaining 2 patients manifested mixed physiology or normal results. Surgical lung biopsy was performed in 2 patients and confirmed the diagnosis of CB in both. Treatment was variable among our patients included glucocorticoids, hydroxychloroquine, mycophenolate mofetil, and cyclophosphamide. Among 6 patients with follow-up computed tomography and pulmonary function, the results remained stable or worsened.ConclusionsConstrictive bronchiolitis is a rare extraglandular manifestation and can sometimes be the presenting manifestation of pSS. This pulmonary manifestation is associated with an indolent clinical course and does not respond well to immunosuppressive therapy.
P4472Targeted sequencing of 80 pharmacogenes reveals evidence for pleiotropic effects on serum LDL cholesterol levels
Nikroo, Nikta Dadkhah, Austin, Erin , Li, R. , Robertson, Peggy D., Stallings, Sarah , Larson, Eric B. , Linneman, James G., Jarvik, G.P., Crosslin, David R. , Schaid, Daniel J. , Network, eMERGE, Safarova, Maya , Andrade, Mariza de , Carrell, David , Bielinski, Suzette J. , Kullo, Iftikhar J. , Network, eMERGE

Mayo Clinic

European Heart Journal | March 29, 2018 | Volume: 38 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehx504.p4472 Get It

Changes in International Normalized Ratios After Plasma Transfusion of Varying Doses in Unique Clinical Environments
Hanson, Andrew C. , Weister, Timothy J. , Higgins, Andrew , Madde, Nageswar R., Schroeder, Darrell R. , Kreuter, Justin D. , Kor, Daryl J. , Higgins, Andrew A, Schroeder, Darrell , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | March 28, 2018 | Volume: 127 | Issue: 2 | Pages: 349-357

10.1213/ane.0000000000003336 | PMID 29596103 Get It

BACKGROUND: Plasma transfusion is commonly performed for the correction of abnormal coagulation screening tests. The goal of this investigation was to assess the relationship between the dose of plasma administered and changes in coagulation test results in a large and diverse cohort of patients with varying levels of coagulation abnormalities and comorbid disease and in a variety of clinical settings. METHODS: In this single-center historical cohort study, all plasma transfusion episodes in adult patients with abnormal coagulation screening tests were extracted between 2011 and 2015. The primary outcome was the proportion of patients attaining normal posttransfusion international normalized ratio (INR ≤ 1.1) with secondary outcomes including the proportion of patients attaining partial normalization of INR (INR ≤ 1.5) or at least 50% normalization in pretransfusion values with respect to an INR of 1.1. RESULTS: In total, 6779 unique patients received plasma with a median (quartiles) pretransfusion INR of 1.9 (1.6–2.5) and a median transfusion volume of 2 (2–3) units. The majority (85%) of transfusions occurred perioperatively, with 20% of transfusions administered prophylactically before a procedure. The median decrease in INR was 0.4 (0.2–0.8). Complete INR normalization was obtained in 12%. Reductions in INR were modest with pretransfusion INR values <3. Patients receiving ≥3 units of plasma were more likely to achieve at least 50% normalization in INR than those receiving ≤2 units (68% vs 60%; P < .001). CONCLUSIONS: Changes in INR after plasma transfusion were modest at typically used clinical doses, particularly in those with less severely deranged baseline coagulation screening tests. Further studies are necessary to assess the relationships between plasma-mediated changes in INR and clinical outcomes.
Double safety reins in wayward B cells
Zeng, Hu

Mayo Clinic

Science Translational Medicine | March 28, 2018 | Volume: 10 | Issue: 434 | Pages: No page available

10.1126/scitranslmed.aat3886 Get It

Two regulatory proteins suppress IRF5 transcription factor in age-associated B cells to prevent systemic autoimmune disorders.
Resistance vs resilience to Alzheimer disease
Arenaza‐Urquijo, Eider M. , Vemuri, Prashanthi , Vemuri, Prashanthi , Arenaza-Urquijo, Eider M

Mayo Clinic

Neurology | March 28, 2018 | Volume: 90 | Issue: 15 | Pages: 695-703

10.1212/wnl.0000000000005303 | PMID 29592885 Get It

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
Lee, Christine H. , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Gerding, Dale N. , Dubberke, Erik R.

Mayo Clinic

Clinical Infectious Diseases | March 28, 2018 | Volume: 67 | Issue: 8 | Pages: 1198-1204

10.1093/cid/ciy259 | PMID 29617739 Get It